Adia Nutrition Announces Subsidiary Adia Med's Submission of Second Clinical Study for IRB Review Targeting Lower Back Pain with AdiaVita

Core Viewpoint - Adia Nutrition Inc. is advancing its clinical research by submitting a second study for its product AdiaVita, aimed at alleviating lower back pain through non-invasive intravenous administration, which could transform pain management practices [1][4][7]. Clinical Study Details - The new clinical study will be a single-blind, placebo-controlled trial involving approximately 100 participants, assessing the efficacy of AdiaVita in reducing inflammation and promoting tissue repair in the lower back [3][4]. - The study will utilize a crossover design, allowing participants in the placebo group to receive AdiaVita after an initial three-month treatment period, facilitating within-subject comparisons [3]. Treatment Methodology - Unlike traditional treatments that require localized injections, this study focuses on systemic delivery via IV infusion, potentially offering a less invasive and more accessible treatment option for patients [4]. Financial Aspects - Participation in the study is structured as a patient-pay model, costing $5,000 per patient, with no additional fees for the crossover phase [5]. Ongoing Research Initiatives - This submission follows Adia Med's ongoing clinical research in Autism Spectrum Disorder (ASD), which is actively recruiting participants and aims to evaluate the combined effects of AdiaVita and glutathione therapy [6][8]. Company Vision and Growth - The CEO of Adia Nutrition expressed enthusiasm about the progress of the lower back pain study, highlighting the company's commitment to advancing patient-centered regenerative therapies that prioritize safety and accessibility [7]. - Adia Nutrition Inc. is expanding its services through Adia Med clinics, which specialize in various regenerative treatments, including stem cell therapies and advanced wound care solutions [10][11].